Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SGN-15

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
PURPOSE Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced… Expand
Is this relevant?
2005
2005
7299 Background: NSCLC cells express tumor antigens, including Lewis Υ (Ley). SGN-15 is a novel antibody-drug conjugate that… Expand
Is this relevant?
2004
2004
7039 Background: Docetaxel (Doc) remains the only FDA approved second line chemotherapy for NSCLC, but response rates and… Expand
Is this relevant?
2003
2003
OBJECTIVEThe SGN-15 monoclonal antibody-doxorubicin immunoconjugate is toxic to LewisY antigen-expressing cells and is effective… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 2
Is this relevant?
2003
2003
  • 2003
  • Corpus ID: 195126662
 
Is this relevant?
Review
2001
Review
2001
  • S. Smith
  • Current opinion in molecular therapeutics
  • 2001
  • Corpus ID: 27000520
Seattle Genetics is developing SGN-15 (BMS-182248, BR96-DOX), a monoclonal antibody-doxorubicin conjugate licensed from Bristol… Expand
Is this relevant?